New combo therapy shows promise for untreatable liver cancer

NCT ID NCT07230080

Ongoing Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a three-part treatment—blocking the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that boost the immune system—can help people with intermediate to advanced liver cancer that cannot be removed by surgery. The 17 participants all received the same combination. Researchers are measuring how many patients' tumors shrink or disappear, how long they live, and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TACE (chemoembolization), SBRT (radiation), and targeted immunotherapy
What this could lead to: If successful, this combination could offer a new treatment option for people with liver cancer that cannot be surgically removed, potentially shrinking tumors and extending survival.
What could go wrong: This is a very small, single-center study with only 17 participants and no comparison group, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy, radiation, and immune system activation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA IMMUNOTHERAPY SBRT TACE TARGETED THERAPY

Contacts and locations

Locations

Nanfang Hosptial

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.